(PRESS RELEASE) CEDAR KNOLLS, NJ — MYOS RENS Technology Inc. (“MYOS” or “the Company”) (NASDAQ: MYOS), a bionutrition company and the owner of Fortetropin, a proprietary bioactive composition that helps build lean muscle, announced that its MYOS Canine Muscle Formula (“MYOS Canine”) Regular and Veterinarian Strength, is now eligible for reimbursement by several top-tier pet insurance companies.
The following pet insurers are now covering MYOS Canine Muscle Formula: Nationwide Pet Insurance, Trupanion Pet Insurance, Embrace Pet Insurance, PetPlan Insurance, Hartville Pet Insurance/Petshealth Care Plan, Prudent Pet Insurance, and PetPartners Pet Insurance. Coverage is on a case-by-case basis and each insurance company should be contacted in advance for details.
Veterinary expenses account for $58.5 billion in spending, annually, according to the North American Pet Health Insurance Association (NAPHIA), and pet insurers reimburse approximately $15.25 billion of those veterinary care costs, annually. Many of these insurers also reimburse a large portion of the cost of nutritional supplements when prescribed by a veterinarian.
“I have been using Fortetropin in dogs for nearly 5 years. I find it particularly helpful in older dogs and canines with muscle atrophy,” stated Leilani Alvarez, DVM, DACVSMR, director, Integrative & Rehabilitative Medicine, Animal Medical Center, New York, NY, an expert on veterinary nutraceuticals who is well-published in this field. “It’s rare to have veterinary supplements backed by prospective clinical studies and, Fortetropin, which has been studied rigorously, is a leader in this regard,” she added.
A vast number of human and veterinary clinical studies have shown that gains in muscle mass and muscular strength are associated with improved longevity for both humans and animals. Additionally, specific veterinary clinical research has also shown that Labrador Retriever dogs with greater muscle mass had improved longevity.
“The decision by many veterinarians to recommend MYOS Canine to their patients is a testament to the efficacy of our product which is backed by high-caliber, published clinical research,” stated Joseph Mannello, CEO of MYOS. “There is overwhelming evidence linking muscle health to improved longevity, and we believe that MYOS Canine is an excellent investment in your dog’s muscle health. We will continue to work with veterinarians and pet insurance companies to offer pet owners a proven product to enhance their dog’s muscle health.”
Advertisement
